Article Text

PDF
The prevalence of cystoid macular oedema in retinitis pigmentosa patients determined by optical coherence tomography
  1. M Hajali1,
  2. G A Fishman1,
  3. R J Anderson2
  1. 1
    Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA
  2. 2
    Department of Epidemiology and Biostatistics, University of Illinois at Chicago, Chicago, IL, USA
  1. Dr G A Fishman, Department of Ophthalmology and Visual Sciences (MC 648), Room 3.85, Eye and Ear Infirmary, 1855 W Taylor Street, Chicago, IL 60612-7234, USA; gerafish{at}uic.edu

Abstract

Aims: To determine the prevalence of cystoid macular oedema (CMO) in retinitis pigmentosa (RP) patients of various genetic subtypes using optical coherence tomography (OCT).

Methods: We performed a complete ocular examination on 124 RP patients including best corrected visual acuity, intraocular pressure measurement, anterior segment and a detailed fundus exam. OCT images were then acquired using two different units. The presence of hypo-reflective lacunae was used to diagnose CMO.

Results: Of the 124 patients, 47 showed CMO in at least one eye (38%), while 34 showed CMO in both eyes (27%). The prevalence of CMO in at least one eye for autosomal dominant (AD) patients was 52%, for autosomal recessive (AR) 39%, isolated 39%, Usher II 35% and none in the X linked recessive (XL) group. Using a chi-square analysis, no statistical significant difference was found for the prevalence of “bilateral CMO” (p = 0.60) or “CMO in at least one eye” (p = 0.59) among the AD, AR, isolated and Usher II genetic subtypes.

Conclusion: Because of its notable prevalence, it would seem prudent to screen RP patients by OCT for the possible presence of CMO, to identify those amenable to treatment and also for future treatment trials when monitoring visual acuity.

Statistics from Altmetric.com

Footnotes

  • Funding: Supported by funds from the Foundation Fighting Blindness, Owings Mills, Maryland; Grant Healthcare Foundation, Lake Forest, Illinois; NIH core grant EYOO1792; and an unrestricted departmental grant from Research to Prevent Blindness. The funding source had no involvement in the design of this study; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

  • Competing interests: None.

  • Ethics approval: This study was approved by an institutional review board and the University of Illinois ethics committee, and was performed in accordance with the tenets of the Declaration of Helsinki.

  • Patient consent: Obtained.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.